TBK1 and hepatocellular carcinoma: Despite these side effects, which diminish antitumor efficacy, contradicting its primary purpose as an anticancer drug, this very inhibition of the TBK1-IFN-mediated innate immune pathway expands sorafenib’s potential in managing HCC recurrence post-liver transplantation (73).